# A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

> **NCT04190823** · PHASE1 · UNKNOWN · sponsor: **RemeGen Co., Ltd.** · enrollment: 63 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** RC98

## Key facts

- **NCT ID:** NCT04190823
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-15
- **Primary completion:** 2023-12-28
- **Final completion:** 2023-12-30
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04190823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04190823, "A Study of RC98 in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04190823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*